Showing 3881-3890 of 8681 results for "".
- New Revenue Cycle Management Service Unveiledhttps://practicaldermatology.com/news/New-Revenue-Cycle-Management-Service-Unveiled/2471638/A new solution to alleviate the challenges posed by insurance claim denials and make it easier for providers to salvage denied claims and increase their reimbursement was on display at the 2025 American Academy of Dermatology (AAD) Annual Meeting in Orlando, Florida, as Nextech previewed the late
- Analysis: Strontium Cream Reduces Pruritus in Hidradenitis Suppurativa Patientshttps://practicaldermatology.com/news/analysis-strontium-cream-reduces-pruritus-in-hidradenitis-suppurativa-patients/2471630/Topical strontium cream significantly alleviates pruritus in patients with hidradenitis suppurativa (HS), according to a recent study published in the Journal of Clinical and Aesthetic Dermatology.
- Remibrutinib Shows Positive Effects on Sleep, Daily Activities for CSU Patientshttps://practicaldermatology.com/news/Remibrutinib-Shows-Positive-Effects-Sleep-Daily-Activities-CSU-Patients/2471637/Remibrutinib’s impact on sleep deprivation and daily activities for patients with chronic spontaneous urticaria (CSU) were highlighted in a presentation at the 2025 American Academy of Dermatology (AAD) Annual Meeting in Orlando, Florida. Robert Snyder, MD, FAAD, presented “Effect of Remib
- Charlotte Dermatology, DOCS Dermatology Group Partner, With PGP as Advisorhttps://practicaldermatology.com/news/Charlotte-Dermatology-DOCS-Dermatology-Group-Partner-With-PGP-Advisor/2471624/Physician Growth Partners (PGP) announced it recently advised Charlotte Dermatology on its partnership with DOCS Dermatology Group (backed by SkyKnight Capital). Founded in 1939, Charlotte Dermatology is one of the longest-standing and most trusted dermatology practices in the Greater Char
- New Tapinarof Data Promising for Children and Perhaps Morehttps://practicaldermatology.com/news/New-Tapinarof-Data-Promising-Children-Perhaps-More/2471623/An analysis of the Phase 3 ADORING 3 study evaluating tapinarof cream, 1% once daily in adults and children 2 years of age and older with atopic dermatitis (AD) presented at the 2025 American Academy of Dermatology (AAD) Annual Meeting in Orlando, Florida, demonstrated that AD disease activity re
- Journey Medical's Claude Maraoui to Speak in 'Fireside Chat' at ROTH Conferencehttps://practicaldermatology.com/news/Journey-Medicals-Claude-Maraoui-Speak-Fireside-Chat-ROTH-Conference/2471608/Journey Medical Corporation president and CEO Claude Maraoui will participate in a “fireside chat” Tuesday, March 18, at the 37th Annual ROTH Conference in Dana Point, California, the company announced. Maraoui’s session will be held at 12:30 p.m. PT, and a webcast will be available for ap
- New Baricitinib AA Data for Adolescents Could Be 'Game-Changing'https://practicaldermatology.com/news/New-Baricitinib-AA-Data-Adolescents-Could-Be-Game-Changing/2471600/Patients ages 12 to under 18 with severe alopecia areata (AA) treated with once-daily, oral baricitinib 4 mg and 2 mg saw clinically meaningful improvements in hair regrowth on the scalp, eyebrows, and eyelashes at Week 36 in the Phase 3 BRAVE-AA-PEDS study, presented as a late-breaker at the 202
- Biologics, JAKs, and More Cited as Potential Treatments for CPUOhttps://practicaldermatology.com/news/Biologics-JAKis-More-Cited-Potential-Treatments-CPUO/2471552/New therapies for chronic pruritus of unknown origin (CPUO) could be close, Gil Yosipovitch, MD, said during his presentation, “What’s Best and What’s Next for Systemic Itch and CPUO” at the 2025 American Academy of Dermatology (AAD) Annual Meeting in Orlando, Florida. “These are patients
- Get In First: A Derm's Case for Early Psoriasis Treatmenthttps://practicaldermatology.com/news/from-aad-2025-a-case-for-early-psoriasis-treatment/2471544/Addressing psoriasis early in its course may lead to prolonged remission and better outcomes, and dermatologists should take note, according to a presentation at the 2025 American Academy of Dermatology Annual Meeting in Orlando.
- ICONIC-LEAD: Icotrokinra Clears Almost Half of Psoriasis Patients in Phase 3 Trialhttps://practicaldermatology.com/news/iconic-lead-icotrokinra-clears-almost-half-of-psoriasis-patients-in-phase-3-trial/2471543/Nearly half of patients with moderate-to-severe plaque psoriasis treated with icotrokinra achieved completely clear skin at week 24, according to new data presented at the 2025 America Academy of Dermatology Annual Meeting. The